Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $153.02 million. The enterprise value is $135.85 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 69.88 million shares outstanding. The number of shares has increased by 4.44% in one year.
| Shares Outstanding | 69.88M |
| Shares Change (YoY) | +4.44% |
| Shares Change (QoQ) | +2.22% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 76.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.39 |
| Quick Ratio | 2.24 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -108.43% and return on invested capital (ROIC) is -73.24%.
| Return on Equity (ROE) | -108.43% |
| Return on Assets (ROA) | -54.15% |
| Return on Capital (ROIC) | -73.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.57M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +124.45% in the last 52 weeks. The beta is 0.70, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +124.45% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 48.83 |
| Average Volume (20 Days) | 648,932 |
Short Selling Information
The latest short interest is 991,569, so 1.42% of the outstanding shares have been sold short.
| Short Interest | 991,569 |
| Short Previous Month | 710,508 |
| Short % of Shares Out | 1.42% |
| Short % of Float | 1.30% |
| Short Ratio (days to cover) | 1.57 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.26M |
| Pretax Income | -21.99M |
| Net Income | -21.44M |
| EBITDA | -23.13M |
| EBIT | -23.26M |
| Earnings Per Share (EPS) | -$0.32 |
Full Income StatementBalance Sheet
The company has $17.55 million in cash and $120,026 in debt, giving a net cash position of $17.43 million or $0.25 per share.
| Cash & Cash Equivalents | 17.55M |
| Total Debt | 120,026 |
| Net Cash | 17.43M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 11.22M |
| Book Value Per Share | 0.16 |
| Working Capital | 11.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.77 million and capital expenditures -$17,202, giving a free cash flow of -$15.54 million.
| Operating Cash Flow | -15.77M |
| Capital Expenditures | -17,202 |
| Free Cash Flow | -15.54M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |